Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1990 2
1997 1
1998 1
2000 1
2001 1
2004 1
2015 1
2018 2
2019 2
2020 1
2021 2
2022 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Pleural Malignant Mesothelioma"
Page 1
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N. Geoerger B, et al. Lancet Oncol. 2020 Jan;21(1):121-133. doi: 10.1016/S1470-2045(19)30671-0. Epub 2019 Dec 4. Lancet Oncol. 2020. PMID: 31812554 Clinical Trial.
Separate reporting of the cohort of patients with relapsed or refractory classical Hodgkin lymphoma was a post-hoc decision. The data cutoff for this interim analysis was Sept 3, 2018. ...Of 136 patients with solid tumours and other lymphomas, eight had partial responses ( …
Separate reporting of the cohort of patients with relapsed or refractory classical Hodgkin lymphoma was a post-hoc decision. The data …
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.
Zauderer MG, Szlosarek PW, Le Moulec S, Popat S, Taylor P, Planchard D, Scherpereel A, Koczywas M, Forster M, Cameron RB, Peikert T, Argon EK, Michaud NR, Szanto A, Yang J, Chen Y, Kansra V, Agarwal S, Fennell DA. Zauderer MG, et al. Lancet Oncol. 2022 Jun;23(6):758-767. doi: 10.1016/S1470-2045(22)00277-7. Epub 2022 May 16. Lancet Oncol. 2022. PMID: 35588752 Clinical Trial.
We aimed to evaluate the anti-tumour activity and safety of tazemetostat in patients with measurable relapsed or refractory malignant pleural mesothelioma. METHODS: We conducted an open-label, single-arm phase 2 study at 16 hospitals in France, the UK, …
We aimed to evaluate the anti-tumour activity and safety of tazemetostat in patients with measurable relapsed or refractory malign …
Expression of Numb and Gli1 in malignant pleural mesothelioma and their clinical significance.
Zhang C, Kang Y, Ma R, Chen F, Chen F, Dong X. Zhang C, et al. J Cancer Res Ther. 2018 Jul-Sep;14(5):970-976. doi: 10.4103/0973-1482.180614. J Cancer Res Ther. 2018. PMID: 30197333 Free article.

AIM OF STUDY: Malignant pleural mesothelioma (MPM) is a highly lethal and refractory to multimodal treatment tumor. ...In addition, Numb has an inverse correlation with ki-67 labeling index (P < 0.05), and nuclear Gli1 was found in associated with t

…
AIM OF STUDY: Malignant pleural mesothelioma (MPM) is a highly lethal and refractory to multimodal treatment tum …
Human epidemiology: a review of fiber type and characteristics in the development of malignant and nonmalignant disease.
Merchant JA. Merchant JA. Environ Health Perspect. 1990 Aug;88:287-93. doi: 10.1289/ehp.9088287. Environ Health Perspect. 1990. PMID: 2272325 Free PMC article. Review.
Consideration of the human epidemiology of diseases arising from exposure to naturally occurring and man-made mineral fibers encompasses the several forms of asbestos (chrysotile, crocidolite, amosite, anthophyllite, tremolite-actinolite), other naturally occurring silicates (tal …
Consideration of the human epidemiology of diseases arising from exposure to naturally occurring and man-made mineral fibers encompasses the …
Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study.
Kitadai R, Shimoi T, Sudo K, Noguchi E, Nagata Y, Sawada R, Takashima A, Boku N, Yonemori K. Kitadai R, et al. BMC Cancer. 2021 Mar 20;21(1):294. doi: 10.1186/s12885-021-08025-x. BMC Cancer. 2021. PMID: 33743636 Free PMC article.
BACKGROUND: Standard treatment for malignant peritoneal mesothelioma has not been established, and systemic chemotherapy is administered according to malignant pleural mesothelioma. ...CONCLUSIONS: Second-line chemotherapy may be an option for …
BACKGROUND: Standard treatment for malignant peritoneal mesothelioma has not been established, and systemic chemotherapy is ad …
Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England.
Damhuis RA, Khakwani A, De Schutter H, Rich AL, Burgers JA, van Meerbeeck JP. Damhuis RA, et al. Lung Cancer. 2015 Aug;89(2):212-7. doi: 10.1016/j.lungcan.2015.05.014. Epub 2015 May 22. Lung Cancer. 2015. PMID: 26044908
INTRODUCTION: Pleural mesothelioma has a dismal prognosis and is refractory to local treatment. ...METHODS: Data from the Belgian Cancer Registry, the Netherlands Cancer Registry and the UK National Lung Cancer Audit were analyzed for patients diagnosed with …
INTRODUCTION: Pleural mesothelioma has a dismal prognosis and is refractory to local treatment. ...METHODS: Data from t …
Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice.
Chahinian AP, Mandeli JP, Gluck H, Naim H, Teirstein AS, Holland JF. Chahinian AP, et al. J Surg Oncol. 1998 Feb;67(2):104-11. doi: 10.1002/(sici)1096-9098(199802)67:2<104::aid-jso6>3.0.co;2-e. J Surg Oncol. 1998. PMID: 9486781
BACKGROUND AND OBJECTIVES: Malignant mesothelioma has a poor prognosis and is refractory to many agents. The antitumor effectiveness of cisplatin, paclitaxel, and suramin as single agents and in combination was evaluated in vivo against four lines of human …
BACKGROUND AND OBJECTIVES: Malignant mesothelioma has a poor prognosis and is refractory to many agents. The antitumor …
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund.
Cerbone L, Delfanti S, Crivellari S, De Angelis AM, Mazzeo L, Proto C, Occhipinti M, Lo Russo G, Dellepiane C, Biello F, Alabiso I, Verderame F, Gauna R, De Simone I, Cuppone F, Petraglia S, Pasello G, Ceresoli GL, Garassino MC, Torri V, Grosso F. Cerbone L, et al. Tumori. 2024 Jun;110(3):168-173. doi: 10.1177/03008916241229287. Epub 2024 Feb 19. Tumori. 2024. PMID: 38372045
BACKGROUND: Pleural mesothelioma is a rare cancer with a dismal prognosis and few therapeutic options, especially in the pretreated setting. Immunotherapy with checkpoint inhibitors as single agents yielded interesting results in refractory pleural …
BACKGROUND: Pleural mesothelioma is a rare cancer with a dismal prognosis and few therapeutic options, especially in the pretr …
Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma.
Takeda M, Ohe Y, Horinouchi H, Hida T, Shimizu J, Seto T, Nosaki K, Kishimoto T, Miyashita I, Yamada M, Kaneko Y, Morimoto C, Nakagawa K. Takeda M, et al. Lung Cancer. 2019 Nov;137:64-70. doi: 10.1016/j.lungcan.2019.09.010. Epub 2019 Sep 16. Lung Cancer. 2019. PMID: 31557561 Free article. Clinical Trial.
OBJECTIVES: CD26 is a transmembrane glycoprotein with dipeptidyl peptidase IV activity that is overexpressed in malignant pleural mesothelioma (MPM). We performed a phase I study to determine the maximum tolerated dose, pharmacokinetics, and antitumor activit …
OBJECTIVES: CD26 is a transmembrane glycoprotein with dipeptidyl peptidase IV activity that is overexpressed in malignant pleural …
Use of an implantable pleural catheter for trapped lung syndrome in patients with malignant pleural effusion.
Pien GW, Gant MJ, Washam CL, Sterman DH. Pien GW, et al. Chest. 2001 Jun;119(6):1641-6. doi: 10.1378/chest.119.6.1641. Chest. 2001. PMID: 11399685
STUDY OBJECTIVES: We describe a series of patients with symptomatic, refractory malignant pleural effusion (MPE) and underlying trapped lung syndrome who underwent placement of a small-bore, flexible indwelling pleural catheter for home drainage of rec …
STUDY OBJECTIVES: We describe a series of patients with symptomatic, refractory malignant pleural effusion (MPE) and un …
18 results